- Datum24.03.2026
- Uhrzeit18:00 - 19:00 Uhr
- Veranstalter
stock3
Syndax Pharmaceuticals Inc. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,76 %
Intraday
1,35 %
1 Woche
17,40 %
1 Monat
14,66 %
Seit Jahresbeginn
75,46 %
1 Jahr
11,68 %
3 Jahre
0,75 %
5 Jahre
90,89 %
10 Jahre
Passender Service zu Syndax Pharmaceuticals Inc.
Webinar zu Syndax Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)8,580-25,440
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Syndax Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Syndax Pharmaceuticals Inc.
- Mai11Syndax Pharmaceuticals Inc.Q1 2026 Earnings Release
- Aug10Syndax Pharmaceuticals Inc.Q2 2026 Earnings Release
- Okt29Syndax Pharmaceuticals Inc.Q3 2026 Earnings Release
Beschreibung
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
